Tag: 2. April 2018

Transparency Market Research observes that the global diabetes drugs market is likely to witness intense competition in the coming years due to a strong presence of several vendors. Companies operating in the global market are expected to widen their product offerings. Furthermore, players are also expected to focus on mergers and acquisitions to expand their markets in the near future. The research report identifies Novo Nordisk A/S, Novartis AG, Merck & Co., Inc., Boehringer Ingelheim GmbH, Bayer AG, and Sanofi as the key players in the global diabetes drugs market.…

Presence of several enterprises has rendered the global anti-venom market highly fragmented. In a new study, Transparency Market Research (TMR) identifies companies such as Bharat Serums and Vaccines Ltd., CSL Behring, Bio-Pharmaceutical Corporation Ltd, Vins Bioproducts Limited, Haffkine Vacsera, and Rare Therapeutics as some of the key market players. These companies adopt diverse policies and strategies to pace up with dynamic consumer preference. While a majority of the companies rely on product launches to strengthen their hold in the market, others forge partnerships and strategic collaborations to expand their regional…

Despite a largely consolidated vendor landscape with several large players and a few regional players, competition in the global myasthenia gravis market is stiff. In this scenario, key players hold small market shares. Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring, Grifols S.A., Baxter International Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International Inc. are to name some prominent companies in the global myasthenia gravis market. These companies are focused on research and development for novel therapeutics for myasthenia gravis. This…

The global spinal fusion devices market is a competitive one with presence of several small as well as large players, says Transparency Market Research (TMR) in a new report. The primary growth strategy adopted by key players include strategic acquisitions and product launches to establish their presence in this competitive market. For instance, in October 2017, NuVasive obtained U.S. FDA 510 (k) clearance for Tlx interbody system employed in Tlif procedures. Following this, in the same month, the company launched Lateral ALIF, XLIF, Crestline, and Lateral MAS Fixation devices to…